These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 24438061

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
    Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM.
    Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [Abstract] [Full Text] [Related]

  • 5. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [Abstract] [Full Text] [Related]

  • 6. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.
    J Clin Oncol; 2007 Jul 20; 25(21):3109-15. PubMed ID: 17577020
    [Abstract] [Full Text] [Related]

  • 7. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
    Kennedy GA, Seymour JF, Wolf M, Januszewicz H, Davison J, McCormack C, Ryan G, Prince HM.
    Eur J Haematol; 2003 Oct 20; 71(4):250-6. PubMed ID: 12950233
    [Abstract] [Full Text] [Related]

  • 8. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R.
    J Clin Oncol; 2015 Nov 10; 33(32):3759-65. PubMed ID: 26261247
    [Abstract] [Full Text] [Related]

  • 9. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R.
    J Am Acad Dermatol; 2003 Jul 10; 49(1):35-49. PubMed ID: 12833006
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
    Quaglino P, Knobler R, Fierro MT, Savoia P, Marra E, Fava P, Bernengo MG.
    Int J Dermatol; 2013 Nov 10; 52(11):1308-18. PubMed ID: 23786842
    [Abstract] [Full Text] [Related]

  • 15. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.
    Elsayad K, Kriz J, Moustakis C, Scobioala S, Reinartz G, Haverkamp U, Willich N, Weishaupt C, Stadler R, Sunderkötter C, Eich HT.
    Int J Radiat Oncol Biol Phys; 2015 Dec 01; 93(5):1077-86. PubMed ID: 26581145
    [Abstract] [Full Text] [Related]

  • 16. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
    Valencak J, Schmid K, Trautinger F, Wallnöfer W, Muellauer L, Soleiman A, Knobler R, Haitel A, Pehamberger H, Raderer M.
    J Dermatol Sci; 2011 Dec 01; 64(3):185-90. PubMed ID: 21937200
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
    Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HH, Prinz BM, Guitart J.
    Arch Dermatol; 2005 Mar 01; 141(3):305-11. PubMed ID: 15781671
    [Abstract] [Full Text] [Related]

  • 18. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
    Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A.
    Cancer; 2003 Sep 01; 98(5):993-1001. PubMed ID: 12942567
    [Abstract] [Full Text] [Related]

  • 19. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.
    Quereux G, Marques S, Nguyen JM, Bedane C, D'incan M, Dereure O, Puzenat E, Claudy A, Martin L, Joly P, Delaunay M, Beylot-Barry M, Vabres P, Celerier P, Sasolas B, Grange F, Khammari A, Dreno B.
    Arch Dermatol; 2008 Jun 01; 144(6):727-33. PubMed ID: 18559761
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.